Next-generation Cologuard Test Demonstrates 94 Percent Sensitivity for Colorectal Cancer at 91 Percent Specificity, Raising the Bar in Non-invasive Screening

BLUE-C study met all endpoints, showing improved cancer sensitivity, specificity, and precancer sensitivity 20,000-participant study reflects racial and ethnic diversity of the U.S. Company plans to complete FDA submission for next-generation Cologuard by end of 2023 MADISON, Wis., June 20, 2023 /PRNewswire/ — Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced … Read more